Analysts Expect Viking Therapeutics, Inc. (VKTX) to Post -$0.17 EPS
Equities analysts predict that Viking Therapeutics, Inc. (NASDAQ:VKTX) will post ($0.17) earnings per share (EPS) for the current fiscal quarter, Zacks reports. Zero analysts have issued estimates for Viking Therapeutics’ earnings. The lowest EPS estimate is ($0.17) and the highest is ($0.16). Viking Therapeutics posted earnings per share of ($0.22) in the same quarter last year, which would suggest a positive year over year growth rate of 22.7%. The firm is expected to issue its next quarterly earnings results on Wednesday, August 9th.
On average, analysts expect that Viking Therapeutics will report full-year earnings of ($0.69) per share for the current year, with EPS estimates ranging from ($0.70) to ($0.68). For the next year, analysts forecast that the business will report earnings of ($0.61) per share, with EPS estimates ranging from ($0.63) to ($0.59). Zacks Investment Research’s earnings per share calculations are a mean average based on a survey of research firms that cover Viking Therapeutics.
Viking Therapeutics (NASDAQ:VKTX) last posted its quarterly earnings data on Tuesday, March 21st. The biotechnology company reported ($0.18) EPS for the quarter, topping analysts’ consensus estimates of ($0.20) by $0.02.
A number of equities research analysts recently weighed in on the company. Maxim Group set a $5.00 price objective on Viking Therapeutics and gave the stock a “buy” rating in a research report on Tuesday, June 6th. HC Wainwright restated a “buy” rating and set a $5.00 price objective on shares of Viking Therapeutics in a research report on Monday, March 27th.
Viking Therapeutics (NASDAQ:VKTX) traded down 2.70% during trading on Tuesday, reaching $1.08. The company’s stock had a trading volume of 297,721 shares. The company’s 50 day moving average price is $1.27 and its 200-day moving average price is $1.31. Viking Therapeutics has a 1-year low of $0.90 and a 1-year high of $1.70. The stock’s market cap is $25.84 million.
Large investors have recently modified their holdings of the company. Vanguard Group Inc. raised its stake in shares of Viking Therapeutics by 22.4% in the first quarter. Vanguard Group Inc. now owns 330,689 shares of the biotechnology company’s stock worth $483,000 after buying an additional 60,467 shares in the last quarter. GRT Capital Partners L.L.C. raised its stake in shares of Viking Therapeutics by 187.8% in the fourth quarter. GRT Capital Partners L.L.C. now owns 94,978 shares of the biotechnology company’s stock worth $113,000 after buying an additional 61,978 shares in the last quarter. Finally, Renaissance Technologies LLC raised its stake in shares of Viking Therapeutics by 62.9% in the first quarter. Renaissance Technologies LLC now owns 265,800 shares of the biotechnology company’s stock worth $388,000 after buying an additional 102,600 shares in the last quarter. Institutional investors and hedge funds own 3.22% of the company’s stock.
Viking Therapeutics Company Profile
Viking Therapeutics, Inc is a clinical-stage biopharmaceutical company. The Company focuses on the development of therapies for metabolic and endocrine disorders. The Company’s clinical program, VK5211, is an orally available drug candidate, which is in Phase II clinical trial for acute rehabilitation following non-elective hip fracture surgery.
For more information about research offerings from Zacks Investment Research, visit Zacks.com
Receive News & Ratings for Viking Therapeutics Inc. Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Viking Therapeutics Inc. and related companies with MarketBeat.com's FREE daily email newsletter.